Sydney, 8 March 2019 (ASX:COH): Cochlear Limited today advises that the National Institute for Health and Care Excellence (NICE) in England has expanded the criteria that health professionals use when determining who is suitable for a cochlear implant within the National Health Service.
The threshold for eligibility has been reduced to equal or greater than 80 dB HL (decibels hearing loss) at two or more frequencies without the use of hearing aids, down from 90 dB HL for children and adults with severe to profound hearing loss.
This important change follows concerted campaigning from advocacy and community associations, healthcare professionals, Cochlear and key groups including the British Academy of Audiology (BAA), the British Society of Audiology (BSA) and the British Cochlear Implant Group (BCIG).
Cochlear's CEO & President, Dig Howitt said, “Cochlear welcomes the news as a positive change that will empower more people to benefit from cochlear implant technology, enabling them to live a full and connected life.
"The UK is a Top 5 market for Cochlear with over 900,000 people living with a severe to profound hearing loss.1 The changes are expected to more than double the number of people in the UK who can now access a cochlear implant."
"We are pleased that there is a growing recognition of the need to set appropriate criteria for cochlear implants. Today’s news follows recent changes in Japan and Taiwan (Greater China) where the expansion of clinical indications and/or reimbursement for cochlear implants has driven growing demand for implants following the changes."
About Cochlear Limited (ASX: COH)
Cochlear is the global leader in implantable hearing solutions. The company has a global workforce of more than 3,500 people and invests more than AUD$160 million a year in research and development. Products include hearing systems for cochlear implants, bone conduction implants and acoustic implants, which are designed to treat a range of moderate to profound types of hearing loss. Since 1981, Cochlear has provided more than 550,000 implantable devices, helping recipients of all ages, in more than 100 countries, to hear and be heard.For further information, please contact:
Analysts Kristina Devon
Head of Investor Relations
(+61) 2 9611 6691
Head of Corporate Communications
(+61) 2 9611 6959
Please seek advice from your health professional about treatments for hearing loss. Outcomes may vary, and your health professional will advise you about the factors which could affect your outcome. Always follow the directions for use. Not all products are available in all countries. Please contact your local Cochlear representative for product information.
Views expressed are those of the individual. Consult your health professional to determine if you are a candidate for Cochlear technology.
In Australia, Cochlear™ Nucleus® implant systems are intended for the treatment of moderately severe to profound hearing loss.
In Australia, Baha® bone conduction implant systems are intended for the treatment of moderate to profound hearing loss.
In Australia, the Cochlear™ Osia® System is indicated for patients with conductive, mixed hearing loss and single-sided sensorineural deafness (SSD) aged 10 years and above with up to 55 decibels sensorineural hearing loss. Patients should have sufficient bone quality and quantity to support successful implant placement. Surgery is required to use this product. Any surgical procedure carries risk.
For Cochlear™ Nucleus®, Osia® and Baha® systems: This product is not available for purchase by the general public. For information on funding and reimbursement please contact your health care professional.
Any testimonial featured on this website is intended for an Australian audience only.
- Hearing Matters 2015, Action on Hearing Loss.